Zacks Investment Research upgraded shares of CRH Medical (NYSEAMERICAN:CRHM) from a sell rating to a hold rating in a research note issued to investors on Tuesday, Zacks.com reports.

According to Zacks, “CRH Medical Corporation offers products and services to physicians for the treatment of gastrointestinal diseases primarily in the United States. The company provides the CRH O’Regan System, a single use, disposable and hemorrhoid banding technology for treating hemorrhoid grades I – IV. It distributes the CRH O’Regan System, treatment protocols, operational and marketing expertise as a complete, turnkey package directly to physicians. The company utilizes Web-based platform to connect doctors with patients as well as educating its install base of physicians. It also offers anesthesia services. CRH Medical Corporation is headquartered in Vancouver, Canada. “

Separately, Bloom Burton raised CRH Medical from an accumulate rating to a buy rating in a report on Thursday, August 1st. One investment analyst has rated the stock with a hold rating and three have given a buy rating to the company. The stock currently has a consensus rating of Buy and a consensus target price of $3.25.

CRH Medical stock opened at $3.21 on Tuesday. CRH Medical has a 52 week low of $2.51 and a 52 week high of $4.50.

CRH Medical (NYSEAMERICAN:CRHM) last posted its earnings results on Wednesday, July 31st. The company reported $0.02 EPS for the quarter, topping the consensus estimate of $0.01 by $0.01. The company had revenue of $30.48 million for the quarter, compared to analyst estimates of $29.50 million.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Renaissance Technologies LLC grew its holdings in CRH Medical by 3.5% in the second quarter. Renaissance Technologies LLC now owns 669,700 shares of the company’s stock valued at $2,029,000 after purchasing an additional 22,500 shares during the period. Wedge Capital Management L L P NC grew its holdings in CRH Medical by 25.7% in the first quarter. Wedge Capital Management L L P NC now owns 118,903 shares of the company’s stock valued at $316,000 after purchasing an additional 24,347 shares during the period. Two Sigma Advisers LP grew its holdings in CRH Medical by 12.6% in the fourth quarter. Two Sigma Advisers LP now owns 220,300 shares of the company’s stock valued at $675,000 after purchasing an additional 24,700 shares during the period. Pacific Ridge Capital Partners LLC grew its holdings in CRH Medical by 1.7% in the second quarter. Pacific Ridge Capital Partners LLC now owns 2,111,335 shares of the company’s stock valued at $6,397,000 after purchasing an additional 34,687 shares during the period. Finally, BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp acquired a new stake in CRH Medical in the first quarter valued at approximately $236,000.

CRH Medical Company Profile

CRH Medical Corporation provides various products and services to gastroenterologists in the United States and Canada. It offers CRH O'Regan system, a single use, disposable, and hemorrhoid banding technology for treating various grades of hemorrhoid. The company also offers anesthesia services for patients undergoing endoscopic procedures.

See Also: How to Use a Moving Average for TradingĀ 

Get a free copy of the Zacks research report on CRH Medical (CRHM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for CRH Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRH Medical and related companies with MarketBeat.com's FREE daily email newsletter.